On October 20, Kodiak Sciences Inc. rose 5.11% in Regular Trading, trading at $96.02 per share, with turnover of $27.49 million.
The move aligns with continuing market focus on two established catalysts: the company previously reported that Zenkuda and tabirafusp-ted met primary endpoints in a Phase 3 wet AMD study, and director Felix Baker later bought about $157 million of shares through Baker Bros. Advisors.
Available disclosures indicate the purchase was made at roughly $80.85 per share and lifted the related institution's stake to about 35%, marking Baker's largest single increase disclosed to date. Separately, the company has said it plans to submit Zenkuda data from five positive Phase 3 studies to regulators in the fourth quarter, covering wet AMD, diabetic retinopathy, and macular edema following retinal vein occlusion. The combination of late-stage clinical progress, a defined regulatory milestone, and sizable insider-backed accumulation has continued to support investor attention.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments